Moderateto highemetogenicrisk TKIsTreatmentfor blastphaseCMLWhen togive H2RAswithdasatinibThe current5-yearoverallsurvival rateof CMLThis TKI hasthe mostmetabolicsyndromeNumber ofblastspresent inacceleratedphaseThe scoringsystem usedin chronicphaseAfter 3months, I have3% BCR-ABL,I have this TKIresponseResponsewhen BCR-ABL1 (IS)is <0.01%Non-pharmacologicaltreatment forCMLTKIs aremajorsubstratesfor this liverenzymeThe numberof distinctclinicalphases inCMLPercentageof blastspresent inthe blastphaseTherecommendedcriteria usedfor acceleratedphaseDrug classthatrevolutionizedCMLtreatmentI have theT315I mutationbut also haveelevated lipaseI want toavoid thisTKI if I donot wantdiarrheaPatients havepresence of thisBCR-ABLproteinindicative ofCML Thelandmarkfor thefirst TKII failed 3lines of TKIs,I can try thisagent nextToo many ofthese bloodcells areabnormal inCML60-70% ofpatients withCML presentwith thissymptomTranslocationbetweenthese twochromosomesoccur in CMLI avoid thisdrug classwith bosutinib,nilotinib anddasatinibModerateto highemetogenicrisk TKIsTreatmentfor blastphaseCMLWhen togive H2RAswithdasatinibThe current5-yearoverallsurvival rateof CMLThis TKI hasthe mostmetabolicsyndromeNumber ofblastspresent inacceleratedphaseThe scoringsystem usedin chronicphaseAfter 3months, I have3% BCR-ABL,I have this TKIresponseResponsewhen BCR-ABL1 (IS)is <0.01%Non-pharmacologicaltreatment forCMLTKIs aremajorsubstratesfor this liverenzymeThe numberof distinctclinicalphases inCMLPercentageof blastspresent inthe blastphaseTherecommendedcriteria usedfor acceleratedphaseDrug classthatrevolutionizedCMLtreatmentI have theT315I mutationbut also haveelevated lipaseI want toavoid thisTKI if I donot wantdiarrheaPatients havepresence of thisBCR-ABLproteinindicative ofCML Thelandmarkfor thefirst TKII failed 3lines of TKIs,I can try thisagent nextToo many ofthese bloodcells areabnormal inCML60-70% ofpatients withCML presentwith thissymptomTranslocationbetweenthese twochromosomesoccur in CMLI avoid thisdrug classwith bosutinib,nilotinib anddasatinib

Chronic Myeloid Leukemia BINGO - Call List

(Print) Use this randomly generated list as your call list when playing the game. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
G
2
I
3
G
4
I
5
O
6
O
7
B
8
I
9
B
10
O
11
I
12
O
13
B
14
N
15
N
16
N
17
B
18
B
19
G
20
O
21
N
22
G
23
G
24
I
  1. G-Moderate to high emetogenic risk TKIs
  2. I-Treatment for blast phase CML
  3. G-When to give H2RAs with dasatinib
  4. I-The current 5-year overall survival rate of CML
  5. O-This TKI has the most metabolic syndrome
  6. O-Number of blasts present in accelerated phase
  7. B-The scoring system used in chronic phase
  8. I-After 3 months, I have 3% BCR-ABL, I have this TKI response
  9. B-Response when BCR-ABL1 (IS) is <0.01%
  10. O-Non-pharmacological treatment for CML
  11. I-TKIs are major substrates for this liver enzyme
  12. O-The number of distinct clinical phases in CML
  13. B-Percentage of blasts present in the blast phase
  14. N-The recommended criteria used for accelerated phase
  15. N-Drug class that revolutionized CML treatment
  16. N-I have the T315I mutation but also have elevated lipase
  17. B-I want to avoid this TKI if I do not want diarrhea
  18. B-Patients have presence of this BCR-ABL protein indicative of CML
  19. G-The landmark for the first TKI
  20. O-I failed 3 lines of TKIs, I can try this agent next
  21. N-Too many of these blood cells are abnormal in CML
  22. G-60-70% of patients with CML present with this symptom
  23. G-Translocation between these two chromosomes occur in CML
  24. I-I avoid this drug class with bosutinib, nilotinib and dasatinib